Strides Pharma (STAR) | Stock Overview & Key Data
Strides Pharma Performance Comparison
Stock Range
Today's Range
Low: ₹804.90
High: ₹834.80
on October 3, 2025
52 Week Range
Low: ₹513.05
High: ₹1,675.00
on April 7, 2025
on October 17, 2024
All-Time High: ₹1,675.00 on October 14, 2024
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR76.7B
EPS
37.11
P/E Ratio (TTM)
22.04
Forward P/E
12.71
P/B Ratio
2.95
PEG Ratio
0.53
Div. Yield
0.74%
ROE
138.93%
Beta
0.496
Debt to Equity
72.67
Financial Highlights
Profitability
Gross Margin
60.32%
Operating Margin
15.11%
Profit Margin
7.38%
Returns and Earnings
Return on Assets (TTM)
59.41%
Return on Equity (TTM)
138.93%
EBITDA
INR8.5B
Net Income (TTM)
INR3.4B
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR502.45
Quarterly Revenue Growth (YoY)
3.00%
Quarterly Earnings Growth (YoY)
41.90%
Dividend Information
Last 12-Month Dividend
₹6.50
Current Dividend Yield
0.74%
3-Year Average Dividend Yield
0.32%
3-Year Average Annual Dividend
₹2.67
3-Year Total Dividends
₹8.00
Ex-Dividend Date
July 22, 2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Strides Pharma STAR | 76.73B Mid-cap | 2.07% | -7.15% | -5.82% | 19.05% | 18.18% | -42.91% | 146.51% | 17.29% |
| Sun Pharmaceutical SUNPHARMA | 4.01T Large-cap | 2.80% | 3.33% | -2.89% | -7.84% | -13.69% | -14.60% | 70.78% | 218.03% |
| Divi's Laboratories DIVISLAB | 1.61T Large-cap | 3.10% | -4.83% | -14.69% | 1.79% | -3.41% | 8.12% | 57.02% | 83.89% |
| Neuland Laboratories NEULANDLAB | 195.16B Mid-cap | 8.80% | 5.76% | 30.23% | 26.07% | 6.30% | 25.94% | 926.28% | 1,106.52% |
| Alembic APLLTD | 182.09B Mid-cap | 0.05% | -4.74% | -9.63% | 2.62% | -13.21% | -26.75% | 47.43% | -5.00% |
| Jubilant Pharmova JUBLPHARMA | 171.19B Mid-cap | -0.50% | 3.66% | -10.84% | 17.71% | -0.05% | -2.93% | 210.44% | 101.03% |
Ownership & Short Interest
Insider Ownership
31.05%
Institutional Ownership
24.68%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
178K
Average 90-Day Volume
220K
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is STAR's 52-week high and low?
- In the last 52 weeks, Strides Pharma reached a high of ₹1,675.00 (on October 17, 2024) and a low of ₹513.05 (on April 7, 2025).
- What is the market cap and P/E ratio for STAR?
- Curious about Strides Pharma's size and valuation? Its market capitalization stands at 76.73B. When it comes to valuation, the P/E ratio (trailing twelve months) is 22.04, and the forward P/E (looking ahead) is 12.71.
- Does STAR pay dividends? If so, what's the yield?
- Yes, Strides Pharma is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 0.74%, and the company has paid an average of ₹2.67 per share annually over the past 3 years.
- Who are Strides Pharma's main competitors or similar companies to consider before investing?
When looking at Strides Pharma, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA4.01T Healthcare Drug Manufacturers - Specialty & Generic -14.60% 70.78% Divi's Laboratories
DIVISLAB1.61T Healthcare Drug Manufacturers - Specialty & Generic 8.12% 57.02% Neuland Laboratories
NEULANDLAB195.16B Healthcare Drug Manufacturers - Specialty & Generic 25.94% 926.28% Alembic
APLLTD182.09B Healthcare Drug Manufacturers - Specialty & Generic -26.75% 47.43% Jubilant Pharmova
JUBLPHARMA171.19B Healthcare Drug Manufacturers - Specialty & Generic -2.93% 210.44% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Strides Pharma Science Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Strides Pharma's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 138.93%, the Debt to Equity ratio from the most recent quarter is 72.67, and its Gross Profit Margin stands at 60.32%.
- What is the recent revenue and earnings growth for STAR?
- Looking at Strides Pharma's growth, its revenue over the trailing twelve months (TTM) was INR46B. Compared to the same quarter last year (YoY), quarterly revenue grew by 3.00%, and quarterly earnings saw a YoY growth of 41.90%.
- How much of STAR stock is held by insiders and institutions?
- Wondering who owns Strides Pharma stock? Company insiders (like executives and directors) hold about 31.05% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 24.68%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.